The meta-analysis conducted by Tang et al. demonstrated that SGLT2 inhibitor administration in patients without chronic kidney disease resulted in a statistically significant elevation of serum magnesium levels compared to placebo control. The gene discussed is SLC5A2; the disease is chronic kidney disease.